Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 13 (2), 112-21

XL-184, a MET, VEGFR-2 and RET Kinase Inhibitor for the Treatment of Thyroid Cancer, Glioblastoma Multiforme and NSCLC

Affiliations
Review

XL-184, a MET, VEGFR-2 and RET Kinase Inhibitor for the Treatment of Thyroid Cancer, Glioblastoma Multiforme and NSCLC

Ying Zhang et al. IDrugs.

Abstract

XL-184 (BMS-907351), under development by Exelixis Inc and Bristol-Myers Squibb Co, is a pan-tyrosine kinase inhibitor for the potential oral treatment of medullary thyroid cancer, glioblastoma multiforme and NSCLC. The prinicipal targets of XL-184 are MET, VEGFR-2 and RET, but the drug is also reported to display inhibitory activity against KIT, FLT3 and TEK. Preclinical studies demonstrated that XL-184 potently inhibited multiple receptor tyrosine kinases in various cancer cell lines and animal xenograft models, and that the drug exhibited significant oral bioavailability and blood-brain barrier penetration. A phase I clinical trial in patients with advanced solid malignancies indicated that XL-184 accumulated dose-dependently in the plasma and had a long terminal half-life. A phase II trial in patients with progressive or recurrent glioblastoma revealed modest but promising median progression-free survival. Toxicity and side effects for the drug have generally been of low-to-moderate severity. At the time of publication, three additional trials of XL-184 were recruiting patients, including a phase I trial in combination with standard of care in patients with glioblastoma, a phase I/II trial in combination with erlotinib in patients with NSCLC, and a phase III trial in patients with medullary thyroid cancer.

Similar articles

See all similar articles

Cited by 38 PubMed Central articles

See all "Cited by" articles

MeSH terms

Substances

Feedback